Indoco Remedies stresses that Form 483s are not data integrity related

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmaceutical drug Fda

Indoco Remedies stresses that Form 483s are not data integrity related
Indoco Remedies says problems the US FDA identified at an ophthalmic and injectable drug plant in Goa, India last month are “correctable.”

The drug and API manufacturer revealed US Food and Drug Administration (FDA) inspectors had issued it with six Form 483s in a filing on the Bombay Stock Exchange BSE) last week​.

According to the document, an FDA team visited its Goa II facility on August 31 in an inspection triggered by the filing of ANDAs for an unnamed injectable drug or drugs in the US.

In the filing Indoco stated that “at the end of the inspection, six 483s were issued. All the observations (483s) are correctable and the Company expects to complete the corrective and preventive actions within a period of 30 days​.”

The Mumbai firm also made clear that none of the 483s “are related to Data Integrity​.”

The FDA has criticized a number​ of Indian drug and API​ firms for their management of manufacturing and quality data in recent months.

Indoco did not respond to a request for comment.

The Goa II facility was approved for the manufacture of solid dose drugs by the FDA in May​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars

Headlines